RTTNews | Jan 25, 2022 07:23AM EST

07:23 Tuesday, January 25, 2022 (RTTNews.com) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) on Tuesday announced the initiation of a clinical trial to evaluate an Omicron-based vaccine candidate in adults 15 to 55 year of age.

The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine, the companies said in a release.

Pfizer And BioNTech further added that first participants enrolled in the study have received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose.

Read the original article on RTTNews ( https://www.rttnews.com/3257006/pfizer-biontech-start-omicron-specific-vaccine-trial-in-adults-aged-15-to-55.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved